[go: up one dir, main page]

WO1992001049A3 - Cd53 cell surface antigen and use thereof - Google Patents

Cd53 cell surface antigen and use thereof Download PDF

Info

Publication number
WO1992001049A3
WO1992001049A3 PCT/US1991/004986 US9104986W WO9201049A3 WO 1992001049 A3 WO1992001049 A3 WO 1992001049A3 US 9104986 W US9104986 W US 9104986W WO 9201049 A3 WO9201049 A3 WO 9201049A3
Authority
WO
WIPO (PCT)
Prior art keywords
cell surface
cloning
mammalian
highly efficient
surface antigens
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1991/004986
Other languages
French (fr)
Other versions
WO1992001049A2 (en
Inventor
Brian Seed
Alejandro Aruffo
Martine Amiot
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Original Assignee
General Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp filed Critical General Hospital Corp
Priority to JP3515602A priority Critical patent/JPH06504186A/en
Priority to AU85286/91A priority patent/AU658370B2/en
Priority to KR1019930700092A priority patent/KR100206524B1/en
Priority to CA002087272A priority patent/CA2087272C/en
Publication of WO1992001049A2 publication Critical patent/WO1992001049A2/en
Anticipated expiration legal-status Critical
Publication of WO1992001049A3 publication Critical patent/WO1992001049A3/en
Priority to KR1019997001739A priority patent/KR100229113B1/en
Priority to KR1019997001740A priority patent/KR100229114B1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

A simple and highly efficient method for cloning cDNAs from mammalian expression libraries based on transient expression in mammalian host cells has been discovered. Novel expression vectors allowing highly efficient construction of mammalian cDNA libraries are disclosed. The cloning method of the invention which has been used to clone genes for cell surface antigens of human lymphocytes, has general application in gene cloning. Cell surface antigens cloned according to the present invention have been purified, and the nucleotide and amino acid sequences determined. These antigens have diagnostic and therapeutic utility in immune-mediated infections in mammals, including humans.
PCT/US1991/004986 1990-07-13 1991-07-15 Cd53 cell surface antigen and use thereof Ceased WO1992001049A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP3515602A JPH06504186A (en) 1990-07-13 1991-07-15 CD53 cell surface antigen and its uses
AU85286/91A AU658370B2 (en) 1990-07-13 1991-07-15 CD53 cell surface antigen and use thereof
KR1019930700092A KR100206524B1 (en) 1990-07-13 1991-07-15 Cd53 cell surface antigen and recombinant dna encoding the same
CA002087272A CA2087272C (en) 1990-07-13 1991-07-15 Cd53 cell surface antigen and use thereof
KR1019997001739A KR100229113B1 (en) 1990-07-13 1999-03-02 Tlisa cell surface antigen and a recombinant dna encoding the same
KR1019997001740A KR100229114B1 (en) 1990-07-13 1999-03-02 Cd27 cell surface antigen and a recombinant dna encoding the same

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55375990A 1990-07-13 1990-07-13
US553,759 1990-07-13

Publications (2)

Publication Number Publication Date
WO1992001049A2 WO1992001049A2 (en) 1992-01-23
WO1992001049A3 true WO1992001049A3 (en) 1993-09-30

Family

ID=24210641

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1991/004986 Ceased WO1992001049A2 (en) 1990-07-13 1991-07-15 Cd53 cell surface antigen and use thereof

Country Status (8)

Country Link
EP (1) EP0551301A1 (en)
JP (3) JPH06504186A (en)
KR (1) KR100206524B1 (en)
AU (1) AU658370B2 (en)
CA (1) CA2087272C (en)
IE (1) IE912466A1 (en)
PT (1) PT98326B (en)
WO (1) WO1992001049A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7132395B1 (en) 1988-09-01 2006-11-07 Bayer Pharmaceuticals Corporation Antiviral methods using human rhinovirus receptor (ICAM-1)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6130202A (en) * 1990-07-20 2000-10-10 Bayer Corporation Antiviral methods
US6107461A (en) * 1990-07-20 2000-08-22 Bayer Corporation Multimeric forms of human rhinovirus receptor and fragments thereof, and method of use
US5316920A (en) * 1992-04-17 1994-05-31 Dana-Faber Cancer Institute, Inc. Lymphocyte activation antigen HB15, a member of the immunoglobulin superfamily
JPH07503024A (en) * 1992-04-30 1995-03-30 シェリング・コーポレーション Modulation of thrombospondin-CD36 interaction
DE69302276T2 (en) * 1992-07-21 1996-09-19 Isis Innovation Diagnostic method
WO1996033217A1 (en) * 1995-04-19 1996-10-24 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Cell adhesion protein, immunosuppressive agent containing the same, and immunosuppressive agent containing cells induced thereby
US5990299A (en) * 1995-08-14 1999-11-23 Icn Pharmaceuticals, Inc. Control of CD44 gene expression for therapeutic use
WO1997020046A1 (en) * 1995-11-30 1997-06-05 Schering Corporation Dnam, an nk antigen and adhesion molecule of the immunoglobulin superfamily
US5863735A (en) * 1997-02-24 1999-01-26 Incyte Pharmaceuticals, Inc. Human transmembrane 4 superfamily protein
US5854022A (en) * 1997-05-13 1998-12-29 Incyte Pharmaceuticals, Inc. Polynucleotides encoding a CD53-like transmembrane protein
US6486299B1 (en) * 1998-09-28 2002-11-26 Curagen Corporation Genes and proteins predictive and therapeutic for stroke, hypertension, diabetes and obesity
EP1006183A1 (en) * 1998-12-03 2000-06-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Recombinant soluble Fc receptors
WO2002044342A2 (en) * 2000-10-18 2002-06-06 The Brigham And Women's Hospital, Inc. Hematopoietic cell e-selection/l-selectin ligand polypeptides and methods of use thereof
WO2005044075A2 (en) * 2003-09-19 2005-05-19 Diadexus, Inc. Compositions, splice variants and methods relating to breast specific genes and proteins
EA015584B1 (en) 2005-03-23 2011-10-31 Генмаб А/С ANTIBODY TO CD38 PERSON AND ITS APPLICATION
US8084236B2 (en) 2006-06-02 2011-12-27 Robert Sackstein Compositions and methods for modifying cell surface glycans
NZ576122A (en) 2006-09-26 2012-09-28 Genmab As Anti-cd38 plus corticosteroids plus a non-corticosteroid chemotherapeutic for treating tumors
EP2090320A1 (en) * 2008-02-15 2009-08-19 Helmholtz-Zentrum für Infektionsforschung GmbH Ligands of the Natural Killer (NK) cell surface marker CD27 and therapeutic uses thereof
WO2011130434A2 (en) 2010-04-13 2011-10-20 Celldex Therapeutics Inc. Antibodies that bind human cd27 and uses thereof
SI2580243T1 (en) 2010-06-09 2020-02-28 Genmab A/S Antibodies against human cd38
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
SG11201701867SA (en) 2014-09-09 2017-04-27 Janssen Biotech Inc Combination therapies with anti-cd38 antibodies
PE20171094A1 (en) 2014-12-04 2017-08-07 Janssen Biotech Inc ANTI-CD38 ANTIBODIES FOR THE TREATMENT OF ACUTE LYMPHOBLASTIC LEUKEMIA
ES2745153T3 (en) * 2014-12-08 2020-02-27 Us Health Anti-cd70 chimeric antigen receptors
CA2986594C (en) 2015-05-20 2025-06-10 Tufts Medical Center Inc Anti-cd38 antibodies for treatment of light chain amyloidosis and other cd38-positive hematological malignancies
UA125115C2 (en) 2015-06-22 2022-01-12 Янссен Байотек, Інк. Method of treating a subject having a multiple mieloma (mm)
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
HRP20220680T1 (en) 2015-11-03 2022-07-08 Janssen Biotech, Inc. Subcutaneous formulations of anti-cd38 antibodies and their uses
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
AU2018359527A1 (en) 2017-10-31 2020-05-07 Janssen Biotech, Inc. Methods of treating high risk multiple myeloma
US20210198374A1 (en) 2018-04-17 2021-07-01 Celldex Therapeutics, Inc. Anti-cd27 and anti-pd-l1 antibodies and bispecific constructs
EP3990015A4 (en) * 2019-06-27 2023-04-26 Verseau Therapeutics, Inc. Anti-cd53 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereof
KR20230161569A (en) 2022-05-18 2023-11-28 엘지전자 주식회사 Hanger and laundry treating appartus having the same
KR20230161572A (en) 2022-05-18 2023-11-28 엘지전자 주식회사 Hanger and laundry treating appartus having the same
KR20230161570A (en) 2022-05-18 2023-11-28 엘지전자 주식회사 Hanger and laundry treating appartus having the same
KR20230161568A (en) 2022-05-18 2023-11-28 엘지전자 주식회사 Hanger and laundry treating appartus having the same
KR20230161571A (en) 2022-05-18 2023-11-28 엘지전자 주식회사 Hanger and laundry treating appartus having the same

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0330191A2 (en) * 1988-02-25 1989-08-30 The General Hospital Corporation DNA encoding CD40

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0330191A2 (en) * 1988-02-25 1989-08-30 The General Hospital Corporation DNA encoding CD40

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
IMMUNOGENETICS, Vol. 32, No. 4, October 1990, SPRINGER INTERNATIONAL, pages 281-285, ANGELISOVA P. et al., "The Human Leukocyte Surface Antigen CD53 is a Protein Structurally Similar to the CD37 and MRC OX-44 Antigens". *
JOURNAL OF IMMUNOLOGY, Vol. 145, No. 12, 15 December 1990, Baltimore, US, pages 4322-4325, AMIOT M. et al., "Identification and Analysis of cDNA Clones Encoding CD53 -A Pan Leukocyte Antigen Related to Membrane Transport Proteins". *
KNAPP W. et al., "Leucocyte Typing IV -White Cell Differentiation Antigens-", 1989, OXFORD UNIVERSITY PRESS, WALTON STREET, OXFORD, GB, "N13 Cluster Report : CD53", pages 674-678. *
KNAPP W. et al., "Leucocyte Typing IV -White Cell Differentiation Antigens-", 1989, OXFORD UNIVERSITY PRESS, WALTON STREET, OXFORD, GB, "N13.1 Reactivity of the Non Lineage/NK Panel Antibodies with Purified Antigens CD45, CD43, CD44 and CD18 and Three 'Novel' Antigens MEM-43, MEM-53 and MEM-102", pages 678-680. *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7132395B1 (en) 1988-09-01 2006-11-07 Bayer Pharmaceuticals Corporation Antiviral methods using human rhinovirus receptor (ICAM-1)

Also Published As

Publication number Publication date
PT98326B (en) 1999-01-29
IE912466A1 (en) 1992-01-15
AU8528691A (en) 1992-02-04
JPH06504186A (en) 1994-05-19
EP0551301A1 (en) 1993-07-21
CA2087272C (en) 2005-10-11
AU658370B2 (en) 1995-04-13
JP2003038179A (en) 2003-02-12
KR100206524B1 (en) 1999-07-01
PT98326A (en) 1992-06-30
WO1992001049A2 (en) 1992-01-23
CA2087272A1 (en) 1992-01-14
JP2001157592A (en) 2001-06-12

Similar Documents

Publication Publication Date Title
WO1992001049A3 (en) Cd53 cell surface antigen and use thereof
EP0330191A3 (en) DNA encoding CD40
US4457867A (en) Physiologically active peptide
Sorace et al. Identification of an endotoxin and IFN‐inducible cDNA: possible identification of a novel protein family
US5702920A (en) DNAS encoding human macrophage migration inhibition factor related peptides
Walder et al. The organization and complete nucleotide sequence of the PstI restriction-modification system.
DK1000146T3 (en) 5 ′ ESTs for non-tissue-specific secreted proteins
Higuchi et al. Human apolipoprotein B (apoB) mRNA: identification of two distinct apoB mRNAs, an mRNA with the apoB-100 sequence and an apoB mRNA containing a premature in-frame translational stop codon, in both liver and intestine.
WO1999006550A3 (en) 5' ESTs FOR SECRETED PROTEINS EXPRESSED IN PROSTATE
IE66712B1 (en) Interleukin-1 inhibitors
WO1999006552A3 (en) 5' ESTs FOR SECRETED PROTEINS EXPRESSED IN BRAIN
CA2015077A1 (en) A yeast cell of the genus schwanniomyces
WO1999006549A3 (en) 5' ESTs FOR SECRETED PROTEINS EXPRESSED IN TESTIS AND OTHER TISSUES
WO1999006551A3 (en) 5' ESTs FOR SECRETED PROTEINS IDENTIFIED FROM BRAIN TISSUES
WO1999006439A3 (en) 5' ESTs FOR SECRETED PROTEINS EXPRESSED IN ENDODERM
CA2020700A1 (en) Compositions for the inhibition of protein hormone formation and uses thereof
WO1999006553A3 (en) 5' ESTs FOR SECRETED PROTEINS EXPRESSED IN VARIOUS TISSUES
Bertolino et al. Cloning and characterization of a mouse type I hair keratin cDNA
Mattei et al. Localization of the gene for human erythrocyte glycophorin C to chromosome 2, q14–q21
WO1995030001A3 (en) Novel p-selectin ligand protein
WO1998011232A3 (en) Human nm23-like protein
ILAN et al. An mRNA bound initiation factor and its role in translation of natural message
JPH1017600A (en) Blood platelet activating factor acetyl hydrolase and its gene
US4935351A (en) Process for preparing oligopeptide
US5683696A (en) Cloning of duffy blood group antigen, gpD

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2087272

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1991916292

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1991916292

Country of ref document: EP

AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP KR

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE

WWR Wipo information: refused in national office

Ref document number: 1991916292

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1991916292

Country of ref document: EP